Tactile Systems Technology reported a strong first quarter with a 23% increase in total revenue year-over-year, driven by growth in both Lymphedema and Airway clearance product lines. The company also saw significant improvements in operating margins on both a GAAP and non-GAAP basis. They raised full year 2023 outlook.
Total revenue increased 23% year-over-year to $58.8 million.
Lymphedema products revenue increased 22% year-over-year.
Airway clearance products revenue increased 24% year-over-year.
Net loss of $1.9 million versus $15.6 million in Q1 2022.
The Company now expects full year 2023 total revenue in the range of approximately $271.0 million to $275.0 million, representing growth of approximately 10% to 11.5% year-over-year.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance